BC Platforms

Central African Republic
Bobangui, Lobaye, Central African Republic, 8002

Company profile

BC Platforms company profile

BCP provides a unique data and technology platform to enable life sciences and healthcare companies to access, manage and analyze clinical and omics data. BCP’s Data Access Platform provides access and related technology to valuable data (RWD, Clinical, Genomics, and Omics) for the Life Science Industry. The Company’s Data Partner Network currently covers more than 22m life-years of highly curated patient data from around the world and is steadily growing. These data are made accessible to Pharma companies through a data-as-a-service (DaaS) model. BCP is able to provide Life Science companies with transformational capabilities to access longitudinal clinical and genome data across the globe to enhance different use cases within the R&D continuum, speeding up the process from early discovery to clinical and post-market access processes. BCP’s technology platform provides technology to Healthcare Providers and Life Science companies to produce, manage and analyze complex genomics as a clinical decision-support solution, analyze the data (genomics- omics and clinical) and make it available for any research ensuring compatibility with all relevant technical standards and in compliance with local privacy law in different jurisdictions.

Business identity

Contact email
[email protected]
Phone number
+41794204749
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
1997-01-01, Year

Headquarters

Postal code
8002
Country code
CF
Continent
Africa

Capital profile

Funding and company signals

Funding stage
Private Equity
Funding rounds
4
Total equity funding
$45.3M
Last funding
Private Equity / $20.3M / 2022-11-08
Last equity funding
Private Equity / $20.3M
Investors
5
Lead investors
5
Founders
1
Articles
79

Founders and investors

Founders

Timo Kanninen

Lead investors

Boston Millennia PartnersDebiopharm Innovation FundIQVIAJolt CapitalTesi

Investors

Boston Millennia PartnersDebiopharm Innovation FundIQVIAJolt CapitalTesi